Biological therapies for the treatment of cutaneous wounds: Phase III and launched therapies

Bibliography

• Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature 2008;453(7193):314-21
   PubMed Web of Science ®Google Scholar
• Sen CK, Gordillo GM, Roy S, et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen 2009;17(6):763-71
   PubMed Web of Science ®Google Scholar
• Cornwell KG, Landsman A, James KS. Extracellular matrix biomaterials for soft tissue repair. Clin Podiatr Med Surg 2009;26(4):507-23
   PubMedGoogle Scholar
• Cole PD, Stal D, Sharabi SE, et al. A comparative, long-term assessment of four soft tissue substitutes. Aesthet Surg J 2011;31(6):674-81
   PubMedGoogle Scholar
• Valentin JE, Badylak JS, McCabe GP, Badylak SF. Extracellular matrix bioscaffolds for orthopaedic applications. A comparative histologic study. J Bone Joint Surg Am 2006;88(12):2673-86
   PubMed Web of Science ®Google Scholar
• Wise DM. Histologic proof that acellular dermal matrices (ADM)–Enduragen, DermaMatrix, and DuraMatrix–are not repopulated or nonviable and that AlloDerm may be repopulated but degraded synchronously. Aesthet Surg J 2012;32(3):355-8
   PubMedGoogle Scholar
• Deeken CR, Melman L, Jenkins ED, et al. Histologic and biomechanical evaluation of crosslinked and non-crosslinked biologic meshes in a porcine model of ventral incisional hernia repair. J Am Coll Surg 2011;212(5):880-8
   PubMed Web of Science ®Google Scholar
• Wainwright D, Madden M, Luterman A, et al. Clinical evaluation of an acellular allograft dermal matrix in full-thickness burns. J Burn Care Rehabil 1996;17(2):124-36
   PubMedGoogle Scholar
• Sinha UK, Shih C, Chang K, Rice DH. Use of AlloDerm for coverage of radial forearm free flap donor site. Laryngoscope 2002;112(2):230-4
   PubMed Web of Science ®Google Scholar
• Kontos AP, Qian Z, Urato NS, et al. AlloDerm grafting for large wounds after Mohs micrographic surgery. Dermatol Surg 2009;35(4):692-8
   PubMed Web of Science ®Google Scholar
• Kinsella CR Jr, Grunwaldt LJ, Cooper GM, et al. Scalp reconstruction: regeneration with acellular dermal matrix. J Craniofac Surg 2010;21(2):605-7
   PubMed Web of Science ®Google Scholar
• de Moya MA, Dunham M, Inaba K, et al. Long-term outcome of acellular dermal matrix when used for large traumatic open abdomen. J Traum 2008;65(2):349-53
   PubMed Web of Science ®Google Scholar
• Reyzelman A, Crews RT, Moore JC, et al. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. Int Wound J 2009;6(3):196-208
   PubMedGoogle Scholar
• Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J 2006;3(3):181-7
   PubMedGoogle Scholar
• Winters CL, Brigido SA, Liden BA, et al. A multicenter study involving the use of a human acellular dermal regenerative tissue matrix for the treatment of diabetic lower extremity wounds. Adv Skin Wound Care 2008;21(8):375-81
   PubMedGoogle Scholar
• Martin BR, Sangalang M, Wu S, Armstrong DG. Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. Int Wound J 2005;2(2):161-5
   PubMedGoogle Scholar
• Mostow EN, Haraway GD, Dalsing M, et al. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vascr Surg 2005;41(5):837-43
   PubMed Web of Science ®Google Scholar
• Romanelli M, Dini V, Bertone MS. Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult-to-heal wounds of mixed arterial/venous etiology. Adv Skin Wound Care 2010;23(1):34-8
   PubMed Web of Science ®Google Scholar
• Romanelli M, Dini V, Bertone M, et al. OASIS wound matrix versus Hyaloskin in the treatment of difficult-to-heal wounds of mixed arterial/venous aetiology. Int Wound J 2007;4(1):3-7
   PubMedGoogle Scholar
• Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care 2005;18(5 Pt 1):258-66
   PubMedGoogle Scholar
• Hodde JP, Ernst DM, Hiles MC. An investigation of the long-term bioactivity of endogenous growth factor in OASIS Wound Matrix. J Wound Care 2005;14(1):23-5
   PubMedGoogle Scholar
• McDevitt CA, Wildey GM, Cutrone RM. Transforming growth factor-beta1 in a sterilized tissue derived from the pig small intestine submucosa. J Biomed Mater Res A 2003;67(2):637-40
   PubMedGoogle Scholar
• Kavros SJ. Acellular fetal bovine dermal matrix for treatment of chronic ulcerations of the midfoot associated with Charcot neuroarthropathy. Foot Ankle Spec 2012;5(4):230-4
   PubMedGoogle Scholar
• Hayn E. Successful treatment of complex traumatic and surgical wounds with a foetal bovine dermal matrix. Int Wound J 2013 March. [Epub ahead of print]
   PubMedGoogle Scholar
• Lullove E. Acellular fetal bovine dermal matrix in the treatment of nonhealing wounds in patients with complex comorbidities. J Am Podiat Med Assn 2012;102(3):233-9
   PubMed Web of Science ®Google Scholar
• Karr JC. Retrospective comparison of diabetic foot ulcer and venous stasis ulcer healing outcome between a dermal repair scaffold (PriMatrix) and a bilayered living cell therapy (Apligraf). Adv Skin Wound Care 2011;24(3):119-25
   PubMedGoogle Scholar
• Lecheminant J, Field C. Porcine urinary bladder matrix: a retrospective study and establishment of protocol. J Wound Care 2012;21(10):476; 478-480, 482
   PubMed Web of Science ®Google Scholar
• Cervelli V, Brinci L, Spallone D, et al. The use of MatriDerm(R) and skin grafting in post-traumatic wounds. Int Wound J 2011;8(4):400-5
   PubMedGoogle Scholar
• Cervelli V, Lucarini L, Cerretani C, et al. The use of Matriderm and autologous skin grafting in the treatment of diabetic ulcers: a case report. Int Wound J 2010;7(4):291-6
   PubMed Web of Science ®Google Scholar
• Heimbach DM, Warden GD, Luterman A, et al. Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment. J Burn Care Rehabil 2003;24(1):42-8
   PubMedGoogle Scholar
• Yeong EK, Chen SH, Tang YB. The treatment of bone exposure in burns by using artificial dermis. Ann Plas Surg 2012;69(6):607-10
   PubMed Web of Science ®Google Scholar
• Branski LK, Herndon DN, Pereira C, et al. Longitudinal assessment of Integra in primary burn management: a randomized pediatric clinical trial. Crit Care Med 2007;35(11):2615-23
   PubMed Web of Science ®Google Scholar
• Kahn SA, Beers RJ, Lentz CW. Use of acellular dermal replacement in reconstruction of nonhealing lower extremity wounds. J Burn Care Res 2011;32(1):124-8
   PubMed Web of Science ®Google Scholar
• Chalmers RL, Smock E, Geh JL. Experience of Integra((R)) in cancer reconstructive surgery. J Plast Reconstr Aesthet Surg 2010;63(12):2081-90
   PubMed Web of Science ®Google Scholar
• Burd A, Wong PS. One-stage integra reconstruction in head and neck defects. J Plast Reconstr Aesthet Surg 2010;63(3):404-9
   PubMed Web of Science ®Google Scholar
• Shores JT, Hiersche M, Gabriel A, Gupta S. Tendon coverage using an artificial skin substitute. J Plast Reconstr Aesthet Surg 2012;65(11):1544-50
   PubMed Web of Science ®Google Scholar
• Weigert R, Choughri H, Casoli V. Management of severe hand wounds with Integra(R) dermal regeneration template. J Hand Surg Eur Vol 2011;36(3):185-93
   PubMedGoogle Scholar
• Stern R, McPherson M, Longaker MT. Histologic study of artificial skin used in the treatment of full-thickness thermal injury. J Burn Care Rehabil 1990;11(1):7-13
   PubMedGoogle Scholar
• Moiemen NS, Vlachou E, Staiano JJ, et al. Reconstructive surgery with Integra dermal regeneration template: histologic study, clinical evaluation, and current practice. Plast Reconstr Surg 2006;117(7 Suppl):160S-74S
   Google Scholar
• Moiemen N, Yarrow J, Hodgson E, et al. Long-term clinical and histological analysis of Integra dermal regeneration template. Plast Reconstr Surg 2011;127(3):1149-54
   PubMed Web of Science ®Google Scholar
• Jeng JC, Fidler PE, Sokolich JC, et al. Seven years' experience with Integra as a reconstructive tool. J Burn Care Res 2007;28(1):120-6
   PubMed Web of Science ®Google Scholar
• Erbatur S, Coban YK, Aydin EN. Comparision of clinical and histopathological results of hyalomatrix usage in adult patients. Int J Burns Trauma 2012;2(2):118-25
   Google Scholar
• Gravante G, Sorge R, Merone A, et al. Hyalomatrix PA in burn care practice: results from a national retrospective survey, 2005 to 2006. Ann Plas Surg 2010;64(1):69-79
   PubMed Web of Science ®Google Scholar
• Gravante G, Delogu D, Giordan N, et al. The use of Hyalomatrix PA in the treatment of deep partial-thickness burns. J Burn Care Res 2007;28(2):269-74
   PubMed Web of Science ®Google Scholar
• Gwosdow AR, Cunningham JJ, Lydon M, et al. Evaporative water losses through a temporary wound dressing under simulated wound conditions. J Burn Care Rehabil 1993;14(4):450-4
   PubMedGoogle Scholar
• Lang EM, Eiberg CA, Brandis M, Stark GB. Biobrane in the treatment of burn and scald injuries in children. Ann Plas Surg 2005;55(5):485-9
   PubMed Web of Science ®Google Scholar
• Ou LF, Lee SY, Chen YC, et al. Use of Biobrane in pediatric scald burns–experience in 106 children. Burns 1998;24(1):49-53
   PubMed Web of Science ®Google Scholar
• Hubik DJ, Wasiak J, Paul E, Cleland H. Biobrane: a retrospective analysis of outcomes at a specialist adult burns centre. Burns 2011;37(4):594-600
   PubMed Web of Science ®Google Scholar
• Kumar RJ, Kimble RM, Boots R, Pegg SP. Treatment of partial-thickness burns: a prospective, randomized trial using Transcyte. ANZ J Surg 2004;74(8):622-6
   PubMed Web of Science ®Google Scholar
• Barret JP, Dziewulski P, Ramzy PI, et al. Biobrane versus 1% silver sulfadiazine in second-degree pediatric burns. Plast Reconstr Surg 2000;105(1):62-5
   PubMed Web of Science ®Google Scholar
• Lesher AP, Curry RH, Evans J, et al. Effectiveness of Biobrane for treatment of partial-thickness burns in children. J Pediatr Surg 2011;46(9):1759-63
   PubMed Web of Science ®Google Scholar
• Rahmanian-Schwarz A, Beiderwieden A, Willkomm LM, et al. A clinical evaluation of Biobrane((R)) and Suprathel((R)) in acute burns and reconstructive surgery. Burns 2011;37(8):1343-8
   PubMed Web of Science ®Google Scholar
• Cassidy C, St Peter SD, Lacey S, et al. Biobrane versus duoderm for the treatment of intermediate thickness burns in children: a prospective, randomized trial. Burns 2005;31(7):890-3
   PubMed Web of Science ®Google Scholar
• Highton L, Wallace C, Shah M. Use of Suprathel(R) for partial thickness burns in children. Burns 2013;39(1):136-41
   PubMed Web of Science ®Google Scholar
• Keck M, Selig HF, Lumenta DB, et al. The use of Suprathel((R)) in deep dermal burns: first results of a prospective study. Burns 2012;38(3):388-95
   PubMed Web of Science ®Google Scholar
• Schwarze H, Kuntscher M, Uhlig C, et al. Suprathel, a new skin substitute, in the management of partial-thickness burn wounds: results of a clinical study. Ann Plas Surg 2008;60(2):181-5
   PubMed Web of Science ®Google Scholar
• Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001;24(2):290-5
   PubMed Web of Science ®Google Scholar
• Edmonds M. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds 2009;8(1):11-18
   PubMed Web of Science ®Google Scholar
• Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen 1999;7(4):201-7
   PubMed Web of Science ®Google Scholar
• Brem H, Balledux J, Bloom T, et al. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg 2000;135(6):627-34
   PubMed Web of Science ®Google Scholar
• Long RE, Falabella AF, Valencia I, et al. Treatment of refractory, atypical lower extremity ulcers with tissue-engineered skin (Apligraf). Arch Dermatol 2001;137(12):1660-1
   PubMed Web of Science ®Google Scholar
• Brem H, Balledux J, Sukkarieh T, et al. Healing of venous ulcers of long duration with a bilayered living skin substitute: results from a general surgery and dermatology department. Dermatol Surg 2001;27(11):915-19
   PubMed Web of Science ®Google Scholar
• Kirsner RS, Warriner R, Michela M, et al. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol 2010;146(8):857-62
   PubMed Web of Science ®Google Scholar
• Shealy FG Jr, DeLoach ED. Experience with the use of apligraf to heal complicated surgical and nonsurgical wounds in a private practice setting. Adv Skin Wound Care 2006;19(6):310-22
   PubMedGoogle Scholar
• Waymack P, Duff RG, Sabolinski M. The effect of a tissue engineered bilayered living skin analog, over meshed split-thickness autografts on the healing of excised burn wounds. The Apligraf Burn Study Group. Burns 2000;26(7):609-19
   PubMed Web of Science ®Google Scholar
• Osborne CS, Schmid P. Epidermal-dermal interactions regulate gelatinase activity in Apligraf, a tissue-engineered human skin equivalent. Br J Dermatol 2002;146(1):26-31
   PubMed Web of Science ®Google Scholar
• Hu S, Kirsner RS, Falanga V, et al. Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study. Wound Repair Regen 2006;14(4):427-33
   PubMed Web of Science ®Google Scholar
• Griffiths M, Ojeh N, Livingstone R, et al. Survival of Apligraf in acute human wounds. Tissue Eng 2004;10(7-8):1180-95
   PubMedGoogle Scholar
• Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging 2007;2(1):93-8
   PubMed Web of Science ®Google Scholar
• Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003;26(6):1701-5
   PubMed Web of Science ®Google Scholar
• Hanft JR, Surprenant MS. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg 2002;41(5):291-9
   PubMedGoogle Scholar
• Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996;19(4):350-4
   PubMed Web of Science ®Google Scholar
• Omar AA, Mavor AI, Jones AM, Homer-Vanniasinkam S. Treatment of venous leg ulcers with Dermagraft. Eur J Vasc Endovas 2004;27(6):666-72
   PubMed Web of Science ®Google Scholar
• Hansbrough JF, Dore C, Hansbrough WB. Clinical trials of a living dermal tissue replacement placed beneath meshed, split-thickness skin grafts on excised burn wounds. J Burn Care Rehabil 1992;13(5):519-29
   PubMedGoogle Scholar
• Purdue GF, Hunt JL, Still JM Jr, et al. A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil 1997;18(1 Pt 1):52-7
   PubMedGoogle Scholar
• Schurr MJ, Foster KN, Centanni JM, et al. Phase I/II clinical evaluation of StrataGraft: a consistent, pathogen-free human skin substitute. J Trauma 2009;66(3):866-73; discussion 873-864
   PubMed Web of Science ®Google Scholar
• Carsin H, Ainaud P, Le Bever H, et al. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a five year single-center experience with 30 patients. Burns 2000;26(4):379-87
   PubMed Web of Science ®Google Scholar
• Uccioli L, Giurato L, Ruotolo V, et al. Two-step autologous grafting using HYAFF scaffolds in treating difficult diabetic foot ulcers: results of a multicenter, randomized controlled clinical trial with long-term follow-up. Int J Low Extrem Wounds 2011;10(2):80-5
   PubMedGoogle Scholar
• Hankin CS, Knispel J, Lopes M, et al. Clinical and cost efficacy of advanced wound care matrices for venous ulcers. J Manag Care Pharm 2012;18(5):375-84
   PubMedGoogle Scholar
• Allenet B, Paree F, Lebrun T, et al. Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the french context. Diabetes Metab 2000;26(2):125-32
   PubMed Web of Science ®Google Scholar
• Thomson SE, McLennan SV, Twigg SM. Growth factors in diabetic complications. Expert Rev Clin Immunol 2006;2(3):403-18
   PubMedGoogle Scholar
• Bao P, Kodra A, Tomic-Canic M, et al. The role of vascular endothelial growth factor in wound healing. J Surg Res 2009;153(2):347-58
   PubMed Web of Science ®Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79(4):1283-316
   PubMed Web of Science ®Google Scholar
• Pierce GF, Mustoe TA, Altrock BW, et al. Role of platelet-derived growth factor in wound healing. J Cell Biochem 1991;45(4):319-26
   PubMed Web of Science ®Google Scholar
• Li W, Fan J, Chen M, et al. Mechanism of human dermal fibroblast migration driven by type I collagen and platelet-derived growth factor-BB. Mol Biol Cell 2004;15(1):294-309
   PubMed Web of Science ®Google Scholar
• Saba AA, Freedman BM, Gaffield JW, et al. Topical platelet-derived growth factor enhances wound closure in the absence of wound contraction: an experimental and clinical study. Ann Plas Surg 2002;49(1):62-6; discussion 66
   PubMed Web of Science ®Google Scholar
• Smiell JM, Wieman TJ, Steed DL, et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999;7(5):335-46
   PubMed Web of Science ®Google Scholar
• Rees RS, Robson MC, Smiell JM, Perry BH. Becaplermin gel in the treatment of pressure ulcers: a Phase II randomized, double-blind, placebo-controlled study. Wound Repair Regen 1999;7(3):141-7
   PubMed Web of Science ®Google Scholar
• Lantis JC II, Boone D, Gendics C, Todd G. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer. Adv Skin Wound Care 2009;22(4):167-71
   PubMed Web of Science ®Google Scholar
• Senet P, Vicaut E, Beneton N, et al. Topical treatment of hypertensive leg ulcers with platelet-derived growth factor-BB: a randomized controlled trial. Arch Dermatol 2011;147(8):926-30
   PubMed Web of Science ®Google Scholar
• Autologous Platelet Derived Growth Factor. Fallon Community Health Plan. 2009. Available at http://www.fchp.org/∼/media/Files/ProviderPDFs/MedicalPolicies/Autologous-PlateletDerivedProducts.ashx [Last accessed 16 June 2013]
   Google Scholar
• Carter MJ, Fylling CP, Li WW, et al. Analysis of run-in and treatment data in a wound outcomes registry: clinical impact of topical platelet-rich plasma gel on healing trajectory. Int Wound J 2011;8(6):638-50
   PubMedGoogle Scholar
• Driver VR, Hanft J, Fylling CP, Beriou JM. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 2006;52(6):68-70; 72, 74 passim
   PubMed Web of Science ®Google Scholar
• King S. Catrix: an easy-to-use collagen treatment for wound healing. Br J Community Nurs 2005;10(9):S31-4
   Google Scholar
• Kirsner RS, Marston WA, Snyder RJ, et al. Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase II, multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2012;380(9846):977-85
   PubMed Web of Science ®Google Scholar
• Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell 2011;9(1):11-15
   PubMed Web of Science ®Google Scholar
• Li L, Baroja ML, Majumdar A, et al. Human embryonic stem cells possess immune-privileged properties. Stem Cells 2004;22(4):448-56
   PubMed Web of Science ®Google Scholar
• Dazzi F, Lopes L, Weng L. Mesenchymal stromal cells: a key player in ‘innate tolerance’? Immunology 2012;137(3):206-13
   PubMed Web of Science ®Google Scholar
• Shin L, Peterson DA. Human mesenchymal stem cell grafts enhance normal and impaired wound healing by recruiting existing endogenous tissue stem/progenitor cells. Stem Cells Transl Med 2013;2(1):33-42
   PubMed Web of Science ®Google Scholar
• Rustad KC, Wong VW, Sorkin M, et al. Enhancement of mesenchymal stem cell angiogenic capacity and stemness by a biomimetic hydrogel scaffold. Biomaterials 2012;33(1):80-90
   PubMed Web of Science ®Google Scholar
• Chang P, Tao K. The use of adipose tissue-derived stem cells within a dermal substitute improves skin regeneration by increasing neoangiogenesis and collagen synthesis. Plast Reconstr Surg 2013;131(1):116e-7e
   Google Scholar
• Hendrickx B, Verdonck K, Van den Berge S, et al. Integration of blood outgrowth endothelial cells in dermal fibroblast sheets promotes full thickness wound healing. Stem Cells 2010;28(7):1165-77
   PubMed Web of Science ®Google Scholar
• Liao Y, Itoh M, Yang A, et al. Human cord blood derived unrestricted Somatic stem cells promote wound healing and have therapeutic potential for patients with recessive dystrophic epidermolysis bullosa. Cell Transplant 2013 Feb. [Epub ahead of print]
   Web of Science ®Google Scholar
• Skardal A, Mack D, Kapetanovic E, et al. Bioprinted amniotic fluid-derived stem cells accelerate healing of large skin wounds. Stem Cells Transl Med 2012;1(11):792-802
   PubMed Web of Science ®Google Scholar
• Sun X, Fu X, Han W, et al. Epidermal stem cells: an update on their potential in regenerative medicine. Expert Opin Biol Ther 2013;13(6):901-10
   PubMed Web of Science ®Google Scholar
• Coruh A, Yontar Y. Reepithelialization from stem cells of hair follicles of dermal graft of the scalp in acute treatment of third-degree burns: first clinical and histologic study. Plast Reconstr Surg 2013;131(2):275e
   Google Scholar
• Oksuz S, Ulkur E, Oncul O, et al. The effect of subcutaneous mesenchymal stem cell injection on statis zone and apoptosis in an experimental burn model. Plast Reconstr Surg 2013;131(3):463-71
   PubMed Web of Science ®Google Scholar
• O'Loughlin A, Kulkarni M, Creane M, et al. Topical administration of allogeneic mesenchymal stem cells seeded in a collagen scaffold augments wound healing and increases angiogenesis in the diabetic rabbit ulcer. Diabetes 2013;62(7):2588-94
   PubMed Web of Science ®Google Scholar
• Blumberg SN, Berger A, Hwang L, et al. The role of stem cells in the treatment of diabetic foot ulcers. Diabetes Res Clin Pract 2012;96(1):1-9
   PubMed Web of Science ®Google Scholar
• Zou JP, Huang S, Peng Y, et al. Mesenchymal stem cells/multipotent mesenchymal stromal cells (MSCs): potential role in healing cutaneous chronic wounds. Int J Low Extrem Wounds 2012;11(4):244-53
   PubMedGoogle Scholar
• Zografou A, Papadopoulos O, Tsigris C, et al. Autologous transplantation of adipose-derived stem cells enhances skin graft survival and wound healing in diabetic rats. Ann Plas Surg 2013;71(2):225-32
   PubMed Web of Science ®Google Scholar
• Dougherty EJ. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care 2008;21(12):568-75
   PubMedGoogle Scholar
• Helary C, Zarka M, Giraud-Guille MM. Fibroblasts within concentrated collagen hydrogels favour chronic skin wound healing. J Tissue Eng Regen Med 2012;6(3):225-37
   PubMed Web of Science ®Google Scholar
• Ermolov AS, Smirnov SV, Khvatov VB, et al. The use of bioactive wound dressing, stimulating epithelial regeneration of IIIa-degree burn wounds. Bull Exp Biol Med 2008;146(1):153-7
   PubMed Web of Science ®Google Scholar
• Wong VW, Rustad KC, Glotzbach JP, et al. Pullulan hydrogels improve mesenchymal stem cell delivery into high-oxidative-stress wounds. Macromol Biosci 2011;11(11):1458-66
   PubMed Web of Science ®Google Scholar
• Nauta A, Seidel C, Deveza L, et al. Adipose-derived stromal cells overexpressing vascular endothelial growth factor accelerate mouse excisional wound healing. Mol Ther 2013;21(2):445-55
   PubMed Web of Science ®Google Scholar
• Brem H, Sheehan P, Boulton AJ. Protocol for treatment of diabetic foot ulcers. Am J Surg 2004;187(5A):1S-10S
   Web of Science ®Google Scholar
• Brem H, Lyder C. Protocol for the successful treatment of pressure ulcers. Am J Surg 2004;188(1A Suppl):9-17
   PubMedGoogle Scholar
• Lal S, Barrow RE, Wolf SE, et al. Biobrane improves wound healing in burned children without increased risk of infection. Shock 2000;14(3):314-18; discussion 318-19
   PubMed Web of Science ®Google Scholar
• Kashefsky H, Marston W. Total contact casting combined with human fibroblast-derived dermal tissue in 15 DFU patients. J Wound Care 2012;21(5):236; 238, 240, 242-233
   PubMedGoogle Scholar
• Warriner RA III, Cardinal M. Human fibroblast-derived dermal substitute: results from a treatment investigational device exemption (TIDE) study in diabetic foot ulcers. Adv Skin Wound Care 2011;24(7):306-11
   PubMedGoogle Scholar
• Embil JM, Papp K, Sibbald G, et al. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. Wound Repair Regen 2000;8(3):162-8
   PubMed Web of Science ®Google Scholar
• Mustoe TA, Cutler NR, Allman RM, et al. A Phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg 1994;129(2):213-19
   PubMed Web of Science ®Google Scholar
• de Leon JM, Driver VR, Fylling CP, et al. The clinical relevance of treating chronic wounds with an enhanced near-physiological concentration of platelet-rich plasma gel. Adv Skin Wound Care 2011;24(8):357-68
   PubMedGoogle Scholar